Gavi and the UK can turn a new page together

13 August 2024

An Expert View from  the new chief executive of Gavi, the Vaccine Alliance, Sania Nishtar.

The last time there was a transition of power in the UK to the Labour Party was 27 years ago in 1997. Gavi, the Vaccine Alliance, did not yet exist. Globally, that year more than 10 million children under-five died from vaccine-preventable diseases like pneumonia, diarrhoea and measles – double the number of deaths of children under-five that we see today. And there were more than 5,000 cases of wild poliovirus recorded in 50 countries in 1997, compared with a handful of cases restricted to just two countries today.

Successive UK governments have played a significant role in these transformations by making political and economic investments in innovations that have paid off by improving health outcomes around the world. Gavi is a prime example. Since the UK helped found Gavi in 2000, the Vaccine Alliance has immunized more than one billion children, prevented more than 17 million deaths, generated more than $200 billion in economic benefits in Gavi-implementing countries, and enabled children to live happier and healthier lives and fulfil their potential. Now, as the alliance plans to vaccinate a further 500 million children between 2026 and 2030, we have a perfect opportunity to reflect on whether global health initiatives like Gavi are still aligned with the government’s priorities.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical